3-Ethyl-7-fluoro-1-benzothiophene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 3-Ethyl-7-fluoro-1-benzothiophene
• 英文别名: 3-ethyl-7-fluoro-1-benzothiophene
• 化学式: C₁₀H₉FS
• 分子量: 180.24
• InChiKey: FMUNOTXRJMKEQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS
  申请人：Alios Bio Pharma, Inc.

  公开号：US20150238498A1

  公开（公告）日：2015-08-27

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了一些新的抗病毒化合物，以及包含一种或多种抗病毒化合物的药物组合物和合成它们的方法。还披露了使用一种或多种小分子化合物改善和/或治疗副黏液病毒病毒感染的方法。副黏液病毒感染的例子包括由人类呼吸道合胞病毒(RSV)引起的感染。
• Heterocyclic compounds as anti-viral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11420976B2

  公开（公告）日：2022-08-23

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： 其可抑制呼吸道合胞病毒（RSV）或HMPV。本发明进一步涉及包含上述化合物的药物组合物，用于给患有 RSV 或 HMPV 感染的受试者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 RSV 或 HMPV 感染的方法。
• HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20210238188A1

  公开（公告）日：2021-08-05

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.